Insilico Medicine Begins Phase I Clinical Trial of ISM6331, a Promising New Inhibitor for Mesothelioma and Solid Tumors, with First Patient Dosed
The First Patient Dosed in a Groundbreaking Phase I Trial of ISM6331 In a significant advancement for cancer research, Insilico Medicine has announced that the...















